Skip to content
Screener

Twist Bioscience Corporation TWST Q4 2026 Annual earnings

Reported November 12, 2026 · Before market open

Revenue$126.6MBeat by $3.1M
EPS-$0.32Beat by $0.07
Revenue estimate$123.5M
EPS estimate-$0.39
“We enter fiscal 2027 with a stronger business and the capital to invest in our next phase of growth. AI is expanding what scientists can design, and personalized medicine is increasing the demand for unique molecules. Both play directly to our strength of customization at scale. We are building the infrastructure for where this industry is going, investing in capacity, automation and new products that enable customers to do more with Twist. Our ambition is to make Twist indispensable to the next generation of discovery, diagnostics and therapeutics.”
Emily M. Leproust

Next report

Feb 1, 2027 (in 2 months)
Revenue estimate$130.8M
EPS estimate-$0.39

Financials

Q4 2026

Income statement

See full
Revenue$126.6M+27.9%
Gross profit$67.3M+32.3%
Operating income-$24.4M+18.4%
Net income-$20.6M+24.0%
EPS (diluted)-$0.30+33.3%

Balance sheet

See full
Cash & equivalents$534.0M+188%
Total debt$110.0M+21.4%
Total equity$888.0M+87.8%
Total assets$1.1B+74.8%

Cash flow

See full
Operating cash flow-$173.0K+98.5%
CapEx$20.0M+60.6%
Free cash flow-$20.1M+17.0%

Valuation & ratios

Valuation

as of 11/10/26
See full
Market cap$8.97B+380%
Enterprise value$8.55B+382%
P/S19.5×+14.6×

Profitability

See full
Gross margin52.4%+1.7pp
Operating margin-30.4%-4.2pp
Net margin-28.3%+16.9pp
FCF margin-19.4%-0.7pp

Returns & leverage

See full
Return on equity-19.1%+3.8pp
Debt / equity0.1×-0.1×
Current ratio5.9×+2.2×

Segments

By geography

See full
Americas$78.8M+37.6%
EMEA$38.7M+11.9%
APAC$9.2M+28.0%

By segment

See full
Reportable Segment$126.6M+27.9%

FAQ

When did Twist Bioscience Corporation report Q4 2026 earnings?
Twist Bioscience Corporation (TWST) reported Q4 2026 earnings on November 12, 2026 before market open.
What were Twist Bioscience Corporation's Q4 2026 revenue and EPS?
Twist Bioscience Corporation reported revenue of $126.6M and eps of $-0.32 for Q4 2026.
Did Twist Bioscience Corporation beat estimates in Q4 2026?
Revenue beat the consensus estimate of $123.5M by $3.1M. EPS beat the consensus estimate of $-0.39 by $0.07.
How did Twist Bioscience Corporation's Q4 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 27.9% from $99.0M a year earlier and eps grew 28.9% from $-0.45.
Where can I find Twist Bioscience Corporation's Q4 2026 SEC filings?
You can read the 8-K earnings release (0001581280-26-000053) and the 10-K periodic report (0001581280-26-000061) directly on SEC EDGAR. The filing index links above go to sec.gov.